DENVER, Colo. (247marketnews.com)– Among the listings positioned for strong sessions are Rain Enhancement Technologies (NASDAQ:RAIN), Butterfly Network (NYSE:BFLY), NeOnc Technologies Holdings (NASDAQ:NTHI), Surgery Partners (NASDAQ:SGRY), Omeros (NASDAQ:OMER), Ginkgo Bioworks (NYSE:DNA), and bioAffinity (NASDAQ:BIAF). Meanwhile, Decoy Therapeutics (NASDAQ:DCOY), Filana Therapeutics (NASDAQ:FLNA), Jaguar Health (NASDAQ:JAGX), Maze Therapeutics (NASDAQ:MAZE), Viking Therapeutics (NASDAQ:VKTX), Greenland Mines (NASDAQ:GRML), and Lianhe Sowell International (NASDAQ:LHSW) remain squarely on the market's high-catalyst radar.
Rain Enhancement Technologies: Betting on a Different Kind of Water Revolution
Rain Enhancement Technologies (NASDAQ:RAIN) is pursuing one of the market's most unconventional technology stories: using atmospheric ionization to influence precipitation. The company's Weather Enhancement Technology Array, or WETA, is designed to enhance rainfall and snowpack without conventional cloud-seeding chemicals. In April, RAIN announced what it called an industry-first guarantee of at least 10% precipitation enhancement for clients deploying its WETA platform.
The company has been working to move the technology from an experimental proposition toward commercial deployments. In August, RAIN reported that a full winter season at its La Sal Mountains site near Moab, Utah, produced greater than 20% snow-water-equivalent enhancement, which it said was independently validated by Utah State University's Dr. Binod Pokharel. RAIN estimated that result represented approximately 8,750 acre-feet of incremental water.
The next part of the story is commercialization. RAIN said Colorado water authorities backed an application for a state-funded pilot in Steamboat Springs, with installation targeted for October 2026, while management is also pursuing fog mitigation and opportunities with municipalities, agriculture and data centers. The company's September investor presentation at the H.C. Wainwright conference highlighted those initiatives as part of its near-term roadmap.
Butterfly Network: Ultrasound Moves Toward the Brain-Computer Interface
Butterfly Network (NYSE: BFLY) spent years trying to turn ultrasound into a more accessible, software-driven medical imaging platform. Its latest development pushes that technology into territory that sounds more like science fiction: brain-computer interfaces. In September, Butterfly announced a multi-year licensing agreement with Merge Labs giving the company access to Butterfly's Poseidon family of Ultrasound-on-Chip technology for development of ultrasound-based neural interfaces.
The deal includes upfront and milestone-based licensing payments, hardware purchase commitments and technology-access fees, with royalties expected on future commercial sales. Butterfly will serve as Merge's exclusive CMOS-MEMS chip-based ultrasound partner, although Butterfly retains the right to license its technology to other companies in the BCI field. The arrangement gives BFLY exposure to a rapidly developing technological category without requiring the company to build the entire neural-interface stack itself.
The partnership comes after Butterfly also expanded handheld-ultrasound availability into Brazil and secured FDA clearance for a blind-sweep ultrasound AI tool earlier in 2026, giving investors multiple threads connecting ultrasound, AI and emerging healthcare applications.
NeOnc Technologies Holdings: New Attack on the Brain's Delivery Barrier
NeOnc (NASDAQ:NTHI) is pursuing one of the most difficult problems in oncology: delivering therapy to the brain. Its lead candidate, NEO100, is an intranasal formulation of purified perillyl alcohol designed to reach the central nervous system through the nasal/olfactory pathway. The approach is particularly relevant to high-grade glioma, where the blood-brain barrier can complicate conventional drug delivery.
The company's August Phase 2a readout generated a significant clinical catalyst. In 24 patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma, NeOnc reported six-month progression-free survival of 48.9%, compared with a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, while five patients remained on treatment at the data cutoff.
The next question is regulatory rather than merely scientific. NeOnc said it plans to request a Type B meeting with the FDA to discuss a potential registrational pathway.
Surgery Partners: $797 Million Changes the Shape of the Story
Surgery Partners (NASDAQ:SGRY) is taking a very different route to a catalyst: portfolio transformation. The company completed the sale of its ownership interests in Idaho Falls Community Hospital and Mountain View Hospital to Intermountain Health, receiving $797 million in gross proceeds and $587 million in net cash proceeds at closing, subject to customary adjustments. (Surgery Partners)
The transaction materially changes the company's financial profile and business mix. Surgery Partners described the deal as positioning it as a more focused short-stay surgical provider.
The company subsequently updated 2026 guidance to revenue of $3.08 billion to $3.18 billion and Adjusted EBITDA of at least $489 million. On a pro forma basis excluding the divested facilities for the full year, management projects revenue of $2.60 billion to $2.67 billion and Adjusted EBITDA of at least $414 million. The market story is therefore shifting from asset ownership toward what SGRY can do with a simplified portfolio and newly available capital.
Omeros Corporation: An Approved Drug Enters the Commercial Phase
Omeros (NASDAQ:OMER) already crossed a major biotechnology threshold: its lead drug, YARTEMLEA, received FDA approval in December 2025 for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, in adults and children two years and older. The company describes YARTEMLEA as the first and only approved therapy for TA-TMA, a potentially life-threatening complication of stem-cell transplantation.
The commercial launch is now the central story. Omeros began commercial distribution in January 2026, and initial orders came from multiple transplant centers. In August, the Centers for Medicare & Medicaid Services granted YARTEMLEA New Technology Add-On Payment status beginning October 1, 2026, potentially providing additional Medicare reimbursement to eligible hospitals treating TA-TMA patients.
Omeros is also working through the European regulatory process. The company's second-quarter update said the EMA's CHMP adopted a negative opinion on the European marketing application and that Omeros requested re-examination. Meanwhile, Omeros reported $132 million in cash and short-term investments at June 30 and said it repurchased $30.5 million of its 2029 notes in July. For OMER, the focus is increasingly on commercialization, reimbursement and international regulatory developments rather than simply another clinical readout. (Omeros)
Ginkgo Bioworks Holdings: Autonomous Labs Add Another AI Layer To Synthetic Biology
Ginkgo Bioworks (NYSE:DNA) is attempting to industrialize biology through automation, software and engineered biological systems. Its latest catalyst comes from a major corporate relationship: in September, Ginkgo announced that it had been selected to build an autonomous laboratory powered by its Reconfigurable Automation Cart architecture at Novo's new U.S. research and development site in Waltham, Massachusetts.
The project adds another dimension to Ginkgo's platform story. Rather than simply selling individual laboratory instruments, the company is positioning automation as infrastructure for faster biological discovery and experimentation. The Novo relationship also deepens an existing multi-year relationship between the companies and demonstrates the potential for Ginkgo's automation architecture to move into major pharmaceutical R&D environments.
The market has already shown sensitivity to major Ginkgo announcements. DNA shares gained more than 11% on September 17 and have experienced several large daily moves in recent weeks. (MarketBeat) The investment narrative remains centered on whether Ginkgo can convert sophisticated biological infrastructure and partnerships into durable commercial growth — making new autonomous-lab deployments an important piece of that larger story.
bioAffinity Technologies: Lung Cancer Detection Expands Its Footprint
bioAffinity (NASDAQ:BIAF) is building its story around CyPath Lung, a noninvasive diagnostic designed to help assess the likelihood of lung cancer using sputum analysis, flow cytometry and fluorescent markers. The company's latest catalyst came September 17, when it announced that Hong Kong's intellectual-property authority granted a patent covering its proprietary technology. (bioAffinity Technologies)
The Hong Kong patent follows a China patent granted in 2025, giving the company additional intellectual-property protection in an important Asian market. CEO Maria Zannes said: “The grant of this patent in Hong Kong and the 2025 patent we received from China strengthen the intellectual property protection for our technology in Asia, a region with a substantial burden of lung cancer.” (SEC)
Commercial development is also advancing. bioAffinity announced a nationwide federal healthcare distribution agreement for CyPath Lung in August and said it was advancing the product for surveillance of lung-cancer survivors in September. The company also regained compliance with Nasdaq listing requirements and completed a $4 million private placement in August. Together, those developments give BIAF a narrative built around intellectual property, distribution and the potential expansion of a noninvasive diagnostic platform. (bioAffinity Technologies)
Today's Other High-Catalyst Movers
Decoy Therapeutics: Ebola Suddenly Expands the Antiviral Story
Decoy Therapeutics (NASDAQ:DCOY) positioned its D-MAV antiviral platform into a much larger potential market after reporting in-vitro activity against wild-type Ebola Zaire virus. Testing was conducted at Texas Biomedical Research Institute, and the company subsequently announced an exploratory program targeting filoviruses including Ebola and Marburg.
The significance is that Decoy's platform was not originally developed specifically around Ebola. The company says its IMP³ACT platform is designed to identify conserved viral-entry mechanisms, potentially allowing one platform to generate antiviral candidates against multiple pathogens.
Viking Therapeutics
The obesity-drug race is rapidly shifting from a simple question of how much weight patients can lose to how conveniently they can maintain those results. That is where Viking Therapeutics (NASDAQ:VKTX) is trying to carve out a differentiated position with VK2735, its dual GLP-1/GIP agonist being developed in both injectable and oral formulations. Reuters reported this week that the broader weight-loss-drug market could reach roughly $100 billion in annual sales within the next decade, intensifying the race among large pharmaceutical companies and smaller biotech developers alike.
Viking's maintenance study is particularly relevant to that next phase of the market. The approximately 180-patient study was designed to examine whether patients who first receive weekly VK2735 can transition to less-frequent maintenance dosing. Viking previously described the study as evaluating weekly, every-other-week and monthly subcutaneous regimens, alongside oral approaches. The company's reported topline results indicate that patients transitioned to every-other-week dosing maintained up to 97% of their previous weight loss, while monthly dosing maintained up to 90%, versus 61% for the placebo-transition group.
The company is simultaneously pushing the program toward pivotal development. Viking said its Phase 3 VANQUISH-1 and VANQUISH-2 trials for injectable VK2735 were fully enrolled as of its second-quarter update, with Phase 3 development of oral VK2735 expected to begin in the fourth quarter of 2026. Earlier oral Phase 2 results showed mean weight loss of as much as 12.2% after 13 weeks, with up to 80% of participants achieving at least 10% weight loss.
CEO Brian Lian framed maintenance flexibility as a central part of the opportunity, saying the company is pursuing dosing options that could support individualized and long-term care after initial weight loss. The investment narrative therefore extends beyond another entrant into the GLP-1 field: Viking is attempting to demonstrate that frequency, formulation and durability can become competitive variables in a market increasingly crowded with heavyweight pharmaceutical players.
Greenland Mines Ltd.
Greenland Mines Ltd. (NASDAQ:GRML) is riding a resource story that has suddenly acquired a geopolitical dimension. Reports that the United States, Denmark and Greenland are preparing to formalize an agreement expanding the U.S. military presence on the strategically important Arctic island, while NATO is expected to play a larger role in Arctic security. The agreement comes as Greenland's deposits of critical minerals have attracted increasing attention from Western governments and companies.
Against that backdrop, Greenland Mines announced September 21 that it had applied for an additional approximately 262-square-kilometer exploration license immediately east of its existing Sarfartoq property. If granted, the expansion would take the company's Sarfartoq footprint from approximately 192 square kilometers to roughly 454 square kilometers — more than doubling its controlled area across the rare-earth district.
The existing ST1 deposit is the economic centerpiece. Greenland Mines reports a combined Indicated-plus-Inferred resource of approximately 12.2 million tonnes grading 1.32% total rare-earth oxides under its hybrid open-pit and underground scenario. An independent Initial Assessment cited by the company produced a high-case pre-tax NPV of approximately $2.05 billion. Importantly, Mineral Resources are not Mineral Reserves and do not demonstrate economic viability, and the newly applied-for 262-square-kilometer area contains no defined Mineral Resource and is not included in the existing economic assessment.
President Dr. Bo Møller Stensgaard said: “This application is about building Sarfartoq at district scale.” He added that the strategy is to advance ST1 toward development while unlocking less-developed zones and testing the broader district for additional rare-earth discoveries. That creates a two-track story for GRML: advance a defined neodymium-praseodymium asset while expanding the exploration footprint at a time when Greenland itself is becoming more strategically significant in the global critical-minerals conversation.
Lianhe Sowell International Group
Lianhe (NASDAQ:LHSW) is putting a potentially powerful distribution channel behind its intelligent-equipment ambitions: a strategic cooperation agreement with Kumquat Technology, a Chery Group subsidiary described by Lianhe Sowell as the operating entity for Chery’s nationwide network of roughly 1,000 4S stores.
Under the agreement, Lianhe Sowell will provide complete intelligent operating equipment covering 24 automotive aftermarket processes, while Kumquat Technology will provide supporting parts and leverage its network to promote the solutions to partner stores and downstream customers. Demonstration sites are also planned, giving prospective customers a chance to see the equipment in operation.
“We are pleased to establish this strategic cooperation with Kumquat Technology and expand the application of our intelligent equipment solutions across the automotive aftermarket,” CEO and Director Yue Zhu said.
The timing puts the announcement squarely in a rapidly digitizing Chinese auto-service market. Industry organizers behind the 2026 Auto Maintenance and Repair Expo have highlighted remote monitoring, preventative diagnostics, electronic inspections and automated maintenance as technologies reshaping aftermarket operations. They also point to the growing importance of new-energy-vehicle maintenance, where diagnostics, battery inspection and other technology-intensive services are becoming increasingly relevant.
For LHSW, the Chery relationship arrives after a year of major corporate and operating developments. Fiscal 2026 revenue rose 18% to $43.27 million, although gross margin declined to 21% and the company posted a $5.65 million net loss as operating expenses jumped 148%, according to its August results.
The company has also been moving aggressively to strengthen its capital position and expand its technology footprint. In September, LHSW closed an $11 million follow-on offering intended to fund product R&D, market expansion, working capital and other corporate purposes.
Now the company is attempting to connect those investments to a much larger commercial opportunity: turning intelligent equipment from individual deployments into a scalable aftermarket model. Lianhe Sowell says the partners also intend to explore overseas opportunities, with Kumquat leading market development and operations while LHSW supplies products and technical support.
About 24/7 Market News
In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.